(S (NP (NP (NP (JJ Adverse) (NN drug) (NNS reactions)) (-LRB- -LRB-) (NP (NNS ADRs)) (-RRB- -RRB-)) (VP (VBN induced) (PP (IN from) (NP (NML (JJ high) (HYPH -) (NN order)) (NML (NN drug) (HYPH -) (NN drug)) (NNS interactions) (PRN (-LRB- -LRB-) (NP (NNS DDIs)) (-RRB- -RRB-)))) (PP (IN due) (PP (IN to) (NP (NN polypharmacy)))))) (VP (VBP represent) (NP (DT a) (JJ significant) (NML (JJ public) (NN health)) (NN problem))) (. .))
(S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP (PRP we)) (ADVP (RB formally)) (VP (VB formulate) (NP (DT the) (NML (NML (PP (IN to) (HYPH -) (NP (NN avoid)))) (CC and) (NML (ADJP (JJ safe) (PP (-LRB- -LRB-) (IN with) (NP (NP (NN respect)) (PP (IN to) (NP (NNS ADRs)))) (-RRB- -RRB-))) (NN drug))) (NN recommendation) (NNS problems)) (SBAR (WHADVP (WRB when)) (S (NP (JJ multiple) (NNS drugs)) (VP (VBP have) (VP (VBN been) (VP (VBN taken) (ADVP (RB simultaneously)))))))) (. .))
(S (NP (PRP We)) (VP (VBP develop) (S (NP (NP (DT a) (JJ joint) (NN model)) (PP (PP (IN with) (NP (DT a) (NN recommendation) (NN component))) (CC and) (PP (NP (DT an) (NN ADR) (NN label) (NN prediction) (NN component)) (IN to)))) (VP (VB recommend) (PP (IN for) (NP (DT a) (NN prescription))) (NP (NP (DT a) (NN set)) (PP (IN of) (NP (NP (NML (PP (IN to) (HYPH -) (NP (NN avoid)))) (NNS drugs)) (SBAR (WHNP (WDT that)) (S (VP (MD will) (VP (VB induce) (NP (NNS ADRs)) (SBAR (IN if) (S (VP (VBN taken) (ADVP (RB together)) (PP (IN with) (NP (DT the) (NN prescription)))))))))))))))) (. .))
(S (NP (PRP We)) (ADVP (RB also)) (VP (VBP develop) (NP (NP (JJ real) (NML (NN drug) (HYPH -) (NN drug)) (NN interaction) (NNS datasets)) (CC and) (NP (VBG corresponding) (NN evaluation) (NNS protocols)))) (. .))
(S (NP (NP (PRP$ Our) (JJ experimental) (NNS results)) (PP (IN on) (NP (JJ real) (NNS datasets)))) (VP (VBP demonstrate) (NP (NP (DT the) (JJ strong) (NN performance)) (PP (IN of) (NP (DT the) (JJ joint) (NN model)))) (PP (VBN compared) (PP (IN to) (NP (JJ other) (NN baseline) (NNS methods))))) (. .))
